Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Trastuzumab untuk terapi adjuvan kanker payudara dini HER2 positif

Penilaian teknologi kesehatan PTK-L01FD01 Draf untuk telaah Diperbarui 12 Juni 2026

1. Latar belakang klinis

Gambaran penyakit

Uraian berikut tersedia dalam bahasa Inggris.

Breast cancer is the most frequently diagnosed malignancy in women worldwide and the leading cancer among Indonesian women. Approximately 15-20% of invasive breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2), a transmembrane tyrosine-kinase receptor whose gene amplification drives uncontrolled proliferation and confers an aggressive natural history with higher recurrence and historically shorter survival than HER2-negative disease in the absence of targeted therapy (Slamon et al., NEJM 2001). HER2 status is determined by immunohistochemistry (IHC 0/1+ negative, 3+ positive), with equivocal 2+ tumours reflexed to in-situ hybridisation (FISH). HER2-positive disease spans early-stage (operable), locally advanced, and metastatic presentations. Trastuzumab (ATC L01FD01), a recombinant humanised anti-HER2 monoclonal antibody, binds the receptor's extracellular domain, inhibiting downstream signalling and recruiting antibody-dependent cell-mediated cytotoxicity. It was the first agent to translate this biomarker into targeted therapy, transforming HER2-positivity from an adverse prognostic marker into a predictive marker of treatment benefit and establishing HER2 status as a mandatory companion diagnostic guiding therapy selection across all stages.

Epidemiologi

Uraian berikut tersedia dalam bahasa Inggris.

Globally, GLOBOCAN 2022 estimated approximately 2.3 million new female breast cancer cases and 670,000 deaths, making it the most commonly diagnosed cancer in women across the majority of countries (IARC GLOBOCAN 2022). In Indonesia, breast cancer is the single most common cancer with an estimated 66,271 new cases in 2022 (ahead of lung 38,904 and cervix uteri 36,964; 22,598 breast cancer deaths), within a national total of roughly 408,661 cancer cases and 242,099 deaths (GLOBOCAN 2022, Indonesia fact sheet). National projections anticipate continued growth, with total cancer cases rising about 63% between 2025 and 2040. HER2-positive disease constitutes an estimated 20-25% of Indonesian breast cancers; population-level series vary, with a Central Java IHC series reporting the HER2-overexpressing subtype at about 20.2% (associated with larger tumours, nodal metastasis, and poorer grade; Widodo et al., 2014), while hospital case series report higher HER2 positivity (e.g., Dharmais Cancer Centre ~45%; ~30.6% in young patients). Critically, Indonesian patients frequently present at advanced stage: in hospital cohorts only ~36% were early stage, ~48% locally advanced, and ~16% metastatic, with roughly 20% diagnosed already metastatic in registry data, owing to substantial diagnostic and referral delays (Sinaga et al., 2023; Anwar et al., 2022).

Terapi standar saat ini

Uraian berikut tersedia dalam bahasa Inggris.

Trastuzumab combined with chemotherapy is the global standard of care for HER2-positive breast cancer and the comparator-defining therapy against chemotherapy alone. In early disease, anti-HER2 therapy with trastuzumab is added to (neo)adjuvant anthracycline/taxane chemotherapy, typically for one year, alongside surgery and, where indicated, radiotherapy and endocrine therapy; two years of trastuzumab confers no additional benefit (HERA; Cameron et al., Lancet 2017), and dual blockade with pertuzumab is used in high-risk node-positive disease. In metastatic disease, first-line standard is dual HER2 blockade with pertuzumab plus trastuzumab plus a taxane, with trastuzumab emtansine and trastuzumab deruxtecan in later lines (NICE TA509; ESMO/NCCN guidelines). The comparator anchoring this appraisal is chemotherapy alone without anti-HER2 therapy, the pre-trastuzumab standard now considered substandard for HER2-positive tumours. Treatment requires baseline and periodic cardiac monitoring (LVEF) given cardiotoxicity risk. In Indonesia, trastuzumab plus chemotherapy is delivered through tertiary oncology centres and has been listed in the national formulary (Fornas) since 2014, supporting use within the JKN/BPJS Kesehatan benefit package, with originator and biosimilar products now available at broadly comparable prices.

Status regulasi dan penjaminan

Uraian berikut tersedia dalam bahasa Inggris.

Trastuzumab (Herceptin) received US FDA approval in 1998 for HER2-overexpressing metastatic breast cancer and EMA marketing authorisation in 2000, with subsequent extension to adjuvant early breast cancer; multiple biosimilars have since been approved by both FDA and EMA. NICE recommends trastuzumab-containing regimens for HER2-positive early and advanced disease, with TA107 covering adjuvant treatment of early HER2-positive breast cancer and TA509 (2018) covering pertuzumab plus trastuzumab and docetaxel for HER2-positive metastatic breast cancer. In Indonesia, trastuzumab is registered with BPOM and has been included in Fornas since 2014; following InaHTAC review the originator was excluded from the formulary in 2018 (use lay dormant 2017-2019), then reinstated in 2020 as biosimilars became available, with originator and biosimilar prices converging to broadly comparable levels (price parity) by 2021 (Setiawan et al., Health Systems & Reform 2024). It is reimbursed under the JKN national health insurance scheme administered by BPJS Kesehatan within defined clinical criteria, making HER2 testing and oncology referral central to access. This contested appraisal history is a documented example of InaHTAC using HTA to influence national medicine pricing and access decisions, with the originator's utilisation rising to 1,292 tablets after 2020 reinstatement before declining to 807 tablets amid biosimilar price parity in 2021.

2. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
Trastuzumab adjuvan selama satu tahun ditambah kemoterapiRp 689,7 juta10,10519,84
kemoterapi standar tanpa terapi anti-HER2Rp 491,0 juta8,29515,22
SelisihRp 198,7 juta1,811-

3. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
01002003000,01,02,03,0Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta100,0%

4. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-40-2002040interventions trastuzumab plus chemotherapy drug cost idr per courseinterventions trastuzumab plus che...annual care costs idr disease freeannual care costs idr disease freeinterventions chemotherapy alone transition rate multipliers disease free to metastasisinterventions chemotherapy alone t...interventions trastuzumab plus chemotherapy transition rate multipliers disease free to metastasisinterventions trastuzumab plus che...annual care costs idr metastasisannual care costs idr metastasisutility values disease freeutility values disease freeinterventions chemotherapy alone transition rate multipliers metastasis to deadinterventions chemotherapy alone t...interventions trastuzumab plus chemotherapy transition rate multipliers metastasis to deadinterventions trastuzumab plus che...interventions chemotherapy alone transition rate multipliers disease free to locoregional recurrenceinterventions chemotherapy alone t...transition rates annual disease free to metastasistransition rates annual disease fr...Perubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

5. Analisis skenario

SkenarioSelisih QALYSelisih biayaRasio per QALY
Base case (50 yr)1,811Rp 198,7 jutaRp 109,7 juta
5-year horizon0,085Rp 97,1 jutaRp 1,1 miliar
10-year horizon0,377Rp 108,0 jutaRp 286,6 juta
20-year horizon1,085Rp 148,5 jutaRp 136,9 juta
0% discount rate3,378Rp 303,5 jutaRp 89,8 juta
5% discount rate1,269Rp 163,0 jutaRp 128,4 juta
Biosimilar trastuzumab at 50% of base price1,811Rp 150,2 jutaRp 83,0 juta
Higher baseline recurrence (late-stage Indonesian presentation, metastasis rate x1.3)1,729Rp 198,6 jutaRp 114,9 juta

6. Validasi model

Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).

Luaran pembandingPrediksi modelData terbitSumber
Annual locoregional recurrence rate, disease-free state (chemotherapy-alone arm)2,9%2,9%Khoirunnisa 2024 PLOS One Indonesia HER2+ early breast cancer model: disease-free to locoregional recurrence 0.029/yr (H
Annual distant-metastasis rate, disease-free state (chemotherapy-alone arm)7,8%7,8%Khoirunnisa 2024 PLOS One: disease-free to metastasis 0.078/yr (HERA-based, chemotherapy-alone arm).
Cumulative all-cause mortality at 10 years (chemotherapy-alone arm)33,7%37,0%HERA observation arm: 10-year disease-free survival 63%, 12-year overall survival 73% (Cameron et al., Lancet 2017). ~10

7. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • NICE recommends trastuzumab-containing regimens for HER2-positive early (TA107) and advanced (TA509) breast cancer; the published directional conclusion is cost-effective/recommended.
  • An Indonesia-specific CEA (Khoirunnisa 2024) found adjuvant trastuzumab cost-effective at the 3x GDP-per-capita threshold (ICER US$6,842/QALY; ~Rp105M/QALY), most favourable in women under 40; this engine reproduces that model with the engine's threshold convention.
  • Trastuzumab is listed in Fornas (since 2014; delisted 2018, reinstated 2020) and reimbursed under JKN; originator and biosimilar prices have converged (price parity by 2021).
  • Budget impact is material because breast cancer is Indonesia's leading female cancer (66,271 cases, 2022 GLOBOCAN) and ~20-25% are HER2-positive; the eligible adjuvant population is large and the drug cost is concentrated in a single treatment year.
  • Equity: late-stage presentation and uneven HER2 testing capacity outside Java-Bali limit real-world access; reliable IHC/ISH companion diagnostics are a precondition for appropriate use.